Suppr超能文献

K-67/MIB-1与垂体腺瘤复发

K -67/MIB-1 and Recurrence in Pituitary Adenoma.

作者信息

Tadokoro Kent, Wolf Colten, Toth Joseph, Joyce Cara, Singh Meharvan, Germanwala Anand, Patel Chirag

机构信息

Department of Otolaryngology-Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois, United States.

State University of New York Upstate Medical University, Syracuse, New York, United States.

出版信息

J Neurol Surg B Skull Base. 2021 Sep 21;83(Suppl 2):e580-e590. doi: 10.1055/s-0041-1735874. eCollection 2022 Jun.

Abstract

K -67/MIB-1 is a marker of cellular proliferation used as a pathological parameter in the clinical assessment of pituitary adenomas, where its expression has shown utility in predicting the invasiveness of these tumors. However, studies have shown variable results when using K -67/MIB-1 association with recurrence. The purpose of this study is to determine if a high K -67/MIB-1 labeling index (LI) is predictive of recurrence in pituitary adenomas.  A retrospective chart review was performed for patients undergoing pituitary adenoma resection with at least 1 year of follow-up. Additionally, systematic data searches were performed and included studies that correlated recurrence rate to K -67/MIB-1 LI. Our institutional data were included in a synthesis with previously published data.  Our institutional review included 79 patients with a recurrence rate of 26.6%. We found that 8.8% of our patients had a high K -67/MIB-1 LI (>3%); however, high K -67/MIB-1 was not associated with recurrence. The systematic review identified 244 articles and 49 full-text articles that were assessed for eligibility. Quantitative analysis was performed on 30 articles including our institutional data and 18 studies reported recurrence by level of K -67/MIB-1 LI. Among studies that compared K -67/MIB-1 ≥3 vs. <3%, 10 studies reported odds ratios (OR) greater than 1 of which 6 were statistically significant. A high K -67/MIB-1 had higher odds of recurrence via the pooled odds ratio (OR = 4.15, 95% confidence interval [CI]: 2.31-7.42).  This systematic review suggests that a high K -67/MIB-1 should prompt an increased duration of follow-up due to the higher odds of recurrence of pituitary adenoma.

摘要

K-67/MIB-1是一种细胞增殖标志物,在垂体腺瘤的临床评估中用作病理参数,其表达已显示出在预测这些肿瘤侵袭性方面的效用。然而,研究表明,使用K-67/MIB-1与复发的关联时结果存在差异。本研究的目的是确定高K-67/MIB-1标记指数(LI)是否可预测垂体腺瘤的复发。

对接受垂体腺瘤切除术且随访至少1年的患者进行了回顾性病历审查。此外,还进行了系统的数据检索,纳入了将复发率与K-67/MIB-1 LI相关联的研究。我们机构的数据与先前发表的数据进行了综合。

我们机构的审查包括79例患者,复发率为26.6%。我们发现,8.8%的患者K-67/MIB-1 LI高(>3%);然而,高K-67/MIB-1与复发无关。系统评价确定了244篇文章和49篇全文文章,并对其进行了资格评估。对30篇文章进行了定量分析,包括我们机构的数据,18项研究报告了按K-67/MIB-1 LI水平的复发情况。在比较K-67/MIB-1≥3%与<3%的研究中,10项研究报告的优势比(OR)大于1,其中6项具有统计学意义。通过合并优势比,高K-67/MIB-1的复发几率更高(OR = 4.15,95%置信区间[CI]:2.31 - 7.42)。

这项系统评价表明,由于垂体腺瘤复发几率较高,高K-67/MIB-1应促使延长随访时间。

相似文献

1
K -67/MIB-1 and Recurrence in Pituitary Adenoma.
J Neurol Surg B Skull Base. 2021 Sep 21;83(Suppl 2):e580-e590. doi: 10.1055/s-0041-1735874. eCollection 2022 Jun.
2
Pathobiology of pituitary adenomas and carcinomas.
Neurosurgery. 2006 Aug;59(2):341-53; discussion 341-53. doi: 10.1227/01.NEU.0000223437.51435.6E.
3
Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Exp Clin Endocrinol Diabetes. 2008 Feb;116(2):80-5. doi: 10.1055/s-2007-991131. Epub 2007 Dec 10.
4
The clinical significance of MIB-1 labeling index in pituitary adenomas.
Pituitary. 2010 Dec;13(4):337-44. doi: 10.1007/s11102-010-0242-7.
5
Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
Neurol Res. 2010 Dec;32(10):1060-71. doi: 10.1179/016164110X12670144737855. Epub 2010 May 18.
7
Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
Acta Neurochir (Wien). 2004 Aug;146(8):831-9. doi: 10.1007/s00701-004-0298-0. Epub 2004 Jun 14.
8
MIB-1 labeling index correlated with magnetic resonance imaging detected tumor volume doubling time in pituitary adenoma.
Eur J Endocrinol. 2010 Jun;162(6):1027-33. doi: 10.1530/EJE-09-1100. Epub 2010 Mar 15.
9
The clinical and pathological significance of nitric oxide synthase in human pituitary adenomas: a comparison with MIB-1.
Endocrine. 2014 May;46(1):154-9. doi: 10.1007/s12020-013-0046-4. Epub 2013 Sep 6.
10
Evaluation of prognostic utility of MIB-1 and p53 expression in pituitary adenomas: correlations with clinical behaviour and follow-up results.
Biotechnol Biotechnol Equip. 2014 May 4;28(3):502-507. doi: 10.1080/13102818.2014.932510. Epub 2014 Aug 22.

引用本文的文献

本文引用的文献

1
Long-term outcomes after endoscopic endonasal surgery for nonfunctioning pituitary macroadenomas.
J Neurosurg. 2020 Jan 31;134(2):535-546. doi: 10.3171/2019.11.JNS192457. Print 2021 Feb 1.
2
Sinonasal quality-of-life outcomes after endoscopic endonasal skull base surgery.
Int Forum Allergy Rhinol. 2019 Oct;9(10):1105-1118. doi: 10.1002/alr.22398. Epub 2019 Jul 29.
6
8
Predictors of surgical outcome and early criteria of remission in acromegaly.
Endocrine. 2018 Jun;60(3):415-422. doi: 10.1007/s12020-018-1590-8. Epub 2018 Apr 6.
9
Clinically aggressive phenotype: A clinicopathological case series of atypical pituitary adenomas.
Clin Neurol Neurosurg. 2018 Apr;167:93-98. doi: 10.1016/j.clineuro.2018.02.001. Epub 2018 Feb 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验